Bacterial Virulence Reduction via GacS/GacA Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively reduce the virulence of bacteria with GacS/GacA-type, HrpX/HrpY-type, and Rsm-type systems, which are involved in regulating virulence factors such as type III secretion systems and biofilm formation, leading to persistent infections.
Innovation Solution
Compounds like p-coumaric acid and cinnamyl alcohol are identified to reduce bacterial virulence by targeting these systems, specifically the GacS/GacA and HrpX/HrpY regulatory pathways, thereby decreasing the expression of virulence-related genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to control bacterial virulence, then bacterial infections persist, but no effective reduction in virulence is achieved
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using specific compounds (p-coumaric acid, cinnamyl alcohol, and their derivatives) that target the GacS/GacA regulatory system. These compounds modify the bacterial regulatory pathways by interfering with the phosphorelay mechanism, thereby changing the expression levels of virulence factors and achieving effective virulence control.
2Object-affected harmful factors
If virulence factors are not controlled, then bacteria maintain pathogenicity, but infections become severe and persistent
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that mediate between the external environment and the bacterial GacS/GacA regulatory system. These compounds act as signaling molecules that bind to components of the two-component system, thereby modulating the transmission of environmental signals and the subsequent regulation of virulence factor expression.
3Adaptability or versatility
If GacS/GacA system is active, then virulence factors are regulated, but bacteria maintain infective capability
Solution Approach 1:
The patent applies preliminary anti-action by using compounds that pre-emptively interfere with the GacS/GacA phosphorelay mechanism before full virulence activation occurs. These compounds bind to key components of the regulatory system in advance, preventing the complete activation of virulence factor expression and thereby controlling bacterial pathogenicity while maintaining some adaptive response capability.
Data Source
AI summary
A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.